MyMedicalRecords to Amend Walgreens Complaint

MyMedicalRecords to Amend Walgreens Complaint 
LOS ANGELES, CA -- (Marketwired) -- 07/01/13 --  MMRGlobal, Inc.
(OTCQB: MMRF), through its wholly owned subsidiary MyMedicalRecords,
Inc. (collectively, "MMR"), today announced that it will seek a
stipulation or order to file an amended complaint against Walgreens
Co. to include claims for infringement of its "Method for Providing a
User with a Service for Accessing and Collecting Prescriptions"
patent currently in the process of being issued under Notice of
Allowance application number 13/714,720 which the Company received on
June 19, 2013. The Prescription Management patent is directed toward
online access and management of prescriptions in retail pharmacies,
mass merchandisers, hospitals and others with pharmacies inside. The
patent covers how consumers, patients, physicians and other
healthcare professionals send prescriptions to the pharmacy, access
prescriptions from a pharmacy, schedule prescription refills, send
reminders regarding prescription refills including by text or email,
and identify adverse drug interactions by analyzing prescription
medications. Based on trends offering consumers the ability to manage
prescriptions online, the Company believes this patent to be
extremely relevant to its business of selling its products and
services and/or licensing its patented intellectual property to
healthcare professionals and others including retail pharmacies such
- Walgreens 
 - Rite Aid 
- CVS 
 - Safeway 
 - Wal-Mart
 - Sam's Club 
- Target  
The list also includes numerous other retailers offering similar
services. The Company also sees its newest health IT patent as
helping drive revenue to its Prepaid Personal Health Record card and
intellectual property pertaining to the use of prescription drug
treatment in clinical trials.  
MMRGlobal already has seven issued U.S. patents pertaining to health
information technologies, including U.S. Patent Nos. 8,301,466;
8,352,287; 8,352,288; 8,121,855; 8,117,646; 8,117,045; and 8,321,240,
as well as additional applications and continuation applications
involving inventions pertaining to Personal Health Records, Patient
Portals and other Electronic Health Record systems in twelve
additional countries including Australia, Singapore, New Zealand,
Mexico, Japan, Canada, China, Hong Kong, South Korea, Israel, and
European nations. The Company's health IT patent portfolio was the
subject of a May 2, 2013 report on Personal Health Records that
concluded that the value of the Company's U.S. patents could reach
between $800 million to $1.1 billion in revenue (at 
For additional information regarding the MyMedicalRecords, Inc.
patent litigation matters, contact Ted Ward at Liner Grode Stein
Yankelevitz Sunshine Regenstreif & Taylor LLP at (310) 500-3384. 
About MMRGlobal
 MMRGlobal, Inc., through its wholly-owned operating
subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use
online Personal Health Records ("PHRs") and electronic safe deposit
box storage solutions, serving consumers, healthcare professionals,
employers, insurance companies, financial institutions, retail
pharmacies, and professional organizations and affinity groups. The
MyMedicalRecords PHR enables individuals and families to access their
medical records and other important documents, such as birth
certificates, passports, insurance policies and wills, anytime from
anywhere using the Internet. MyMedicalRecords is built on
proprietary, patented technologies to allow documents, images and
voicemail messages to be transmitted and stored in the system using a
variety of methods, including fax, phone, or file upload without
relying on any specific electronic medical record platform to
populate a user's account. The Company's professional offering,
MMRPro, is designed to give physicians' offices an easy and
cost-effective solution to digitizing paper-based medical records and
sharing them with patients through an integrated patient portal.
Through its merger with Favrille, Inc. in January 2009, the Company
acquired intellectual property biotech assets that include anti-CD20
antibodies and data and samples from its FavId(TM)/Specifid(TM)
vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's
lymphoma. To learn more about MMRGlobal, Inc. visit View demos and video tutorials of the Company's
products and services at 
Forward-Looking Statements 
 All statements in this press release
that are not strictly historical in nature, including, without
limitation, intellectual property enforcement actions, infringement
claims or litigation, intellectual property licenses, and future
performance, management's expectations, beliefs, intentions,
estimates or projections, constitute "forward-looking statements."
Such forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause MMR's actual results
to be materially different from historical results or from any
results expressed or implied by such forward-looking statements. Some
can be identified by the use of words (and their derivations) such as
"need," "possibility," "potential," "intend," "offer," "development,"
"if," "negotiate," "when," "begun," "believe," "achieve," "will,"
"estimate," "expect," "maintain," "plan," and "continue," or the
negative of these words. Actual outcomes and results of operations
and the timing of selected events may differ materially from the
results predicted, and any reported results should not be considered
as an indication of future performance. Such statements are
necessarily based on assumptions and estimates and are subject to
various risks and uncertainties, including those relating to the
possible invalidity of the underlying assumptions and estimates and
possible changes or developments in economic, business, industry,
market, legal and regulatory circumstances and conditions and actions
taken or omitted to be taken by third parties, including customers,
suppliers, business partners, potential licensees, competitors and
legislative, judicial and other governmental authorities and
officials. Factors that could cause or contribute to such differences
include, but are not limited to: unexpected outcomes with respect to
intellectual property enforcement actions, claims of intellectual
property infringement and general intellectual property litigation;
our ability to maintain, develop, monetize and protect our patent
portfolio for both MMR's health IT and biotechnology intellectual
property assets in the U.S. and internationally; the timing of
milestone payments in connection with licensing our intellectual
property; our ability to establish and maintain strategic
relationships; changes in our relationships with our licensees; the
risk MMR's products are not adopted or viewed favorably by the
healthcare community and consumer retail market; business prospects,
results of operations or financial condition; risks related to the
current uncertainty and instability in financial and lending markets,
including global economic uncertainties; the timing and volume of
sales and installat
ions; the length of sales cycles and the
installation process; the market's acceptance of new product and
service introductions; competitive product offerings and promotions;
changes in government laws and regulations including the 2009 HITECH
Act and changes in Meaningful Use and the 2010 Affordable Care Act;
future changes in tax legislation and initiatives in the healthcare
industry; undetected errors in our products; the possibility of
interruption at our data centers; risks related to third party
vendors; risks related to obtaining and integrating third-party
licensed technology; risks related to a security breach by third
parties; risks associated with recruitment and retention of key
personnel; other litigation matters; uncertainties associated with
doing business internationally across borders and territories; and
additional risks discussed in MMR's filings with the Securities and
Exchange Commission, including disclosures about relationship with
the Michael Bass Group since 2009. MMR is providing this information
as of the date of this release and, except as required by applicable
law, does not undertake any obligation to update any forward-looking
statements contained in this release as a result of new information,
future events or otherwise.   
Michael Selsman
Public Communications Co.
(310) 922-7033 
Press spacebar to pause and continue. Press esc to stop.